Clinical Trials

33 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3 Recruiting

266 enrolled

Nasopharyngeal Carcinoma

NCT07371611 2026-01-28

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Phase 3 Recruiting

104 enrolled

Phase 4 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Phase 3 Not yet recruiting

Thyroid Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Nasopharyngeal Carcinoma

NCT06494943 2025-02-25

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Phase 1/2 Recruiting

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06787911 2025-01-22

Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer

14 enrolled

Phase 2 Not yet recruiting

Thyroid Neoplasms

NCT06680115 2024-11-08

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

150 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04718415 2024-09-19

OOC-001

51 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

60 enrolled

Nasopharyngeal Carcinoma

NCT05098119 2024-03-26

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

43 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06240689 2024-02-05

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

104 enrolled

Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT04072107 2023-06-18

EP-STAR

110 enrolled

Nasopharyngeal Carcinoma

NCT03700476 2023-03-28

CONTINUUM

Phase 3 Unknown

425 enrolled

Nasopharyngeal Neoplasms

NCT05749042 2023-03-01

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

70 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04872582 2023-02-23

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

33 enrolled

Nasopharyngeal Carcinoma

NCT05000892 2022-12-02

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Head & NeckOther neoplasm

15 enrolled

Salivary Gland Malignant Neoplasms

NCT05136768 2021-11-29

LM-HNSCC

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT04917770 2021-06-08

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

28 enrolled

Nasopharyngeal Carcinoma

NCT04882462 2021-05-12

Carpp-1

100 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04769076 2021-02-25

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

40 enrolled

Nasopharyngeal Carcinoma

NCT04065737 2019-08-22

STOP

Head & NeckOther neoplasm

29 enrolled

Mouth Neoplasms, Precancerous Conditions

NCT03975270 2019-07-18

HNSCC

41 enrolled

Head and Neck Squamous Cell Cancer

NCT03619824 2018-10-09

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

40 enrolled